QR kód

Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score–matched analysis

Introduction: Liver metastasis (LM) confers a poor prognosis in patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment, the optimal approach for this high-risk subgroup rem...

Celý popis

Uloženo v:
Hlavní autoři: Wen Zhang, Zhou Long, Xiaoli He, Xuemei Wu, Jian Wen, Dongfan Ye, Jia Chen, Guansong Wang
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2026-01-01
Edice:Cancer Treatment and Research Communications
Témata:
EGFR mutation
Non-small cell lung cancer
Liver metastasis
Combination therapy
Chemotherapy
TKI
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2468294226000171
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky